{"id":1021148,"date":"2026-11-16T06:04:32","date_gmt":"2026-11-16T11:04:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/"},"modified":"2026-11-16T06:04:32","modified_gmt":"2026-11-16T11:04:32","slug":"anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/","title":{"rendered":"Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MINNEAPOLIS and BRISBANE, Australia, Nov.  16, 2026  (GLOBE NEWSWIRE) &#8212; <strong>Anteris Technologies Global Corp.<\/strong> (\u201cAnteris\u201d or the \u201cCompany\u201d) (Nasdaq: AVR; ASX: AVR) today announced that Rishi Puri, MD, PhD, Cleveland Clinic, will present one-year clinical and hemodynamic outcomes for the DurAVR<sup>\u00ae<\/sup> Transcatheter Heart Valve (THV) in a late-breaking session at PCR London Valves, held November 22\u201324, 2026, in London, United Kingdom.<\/p>\n<p align=\"justify\">The presentation will report one-year clinical and hemodynamic outcomes from a pooled cohort of 100 patients with severe aortic stenosis who received the DurAVR THV. The DurAVR THV is a biomimetic, balloon-expandable valve and a new class of transcatheter aortic valve replacement (TAVR).<\/p>\n<p align=\"justify\">\n        <strong>Session details are as follows:<br \/><\/strong><br \/>\n        <strong>Session: <\/strong>TAVI Hotline \u2013 Part 1<br \/><strong>Track: <\/strong>Hotline \/ Late-Breaking Trials<br \/><strong>Date and time: <\/strong>Sunday, November 22, 2026, 9:30 AM \u2013 10:30 AM GMT\/UTC+0<br \/><strong>Location: <\/strong>Dubai Room<br \/><strong>Title: <\/strong>One-Year Clinical and Hemodynamic Outcomes of a Novel Biomimetic Balloon-Expandable THV in Small Aortic Annuli<br \/><strong>Presenter: <\/strong>Rishi Puri, MD, PhD, Cleveland Clinic<\/p>\n<p align=\"justify\">\n        <strong>About Anteris<\/strong>\n      <\/p>\n<p align=\"justify\">Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.<\/p>\n<p align=\"justify\">Anteris\u2019 lead product, the DurAVR THV, was designed in collaboration with the world\u2019s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis \u2013 a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR THV is made using a single piece of molded ADAPT<sup>\u00ae<\/sup> tissue, Anteris\u2019 patented anti-calcification tissue technology. ADAPT tissue, which is FDA-cleared, has been used clinically for over 10\u00a0years and distributed for use in over 55,000 patients worldwide. The DurAVR THV System is comprised of the DurAVR valve, the ADAPT tissue, and the balloon-expandable ComASUR<sup>\u00ae<\/sup> Delivery System.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words \u201cbelieve,\u201d \u201cproject,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cbudget,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cstrategy,\u201d \u201cplan,\u201d \u201cguidance,\u201d \u201coutlook,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cwill be,\u201d \u201cwill continue,\u201d \u201cwill likely result\u201d and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under \u201cRisk Factors\u201d in Anteris\u2019 Annual Report on Form 10-K for the fiscal period ended December 31, 2025 that was filed with the Securities and Exchange Commission and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%\">\n            <strong>For more information:<\/strong>\n          <\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Global Investor Relations<\/strong>\n          <\/td>\n<td>\n            <strong>Investor Relations (US)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>investors@anteristech.com<\/td>\n<td>mchatterjee@bplifescience.com<\/td>\n<\/tr>\n<tr>\n<td>Debbie Ormsby<\/td>\n<td>Malini Chatterjee, Ph.D.<\/td>\n<\/tr>\n<tr>\n<td>Anteris Technologies Global Corp.<\/td>\n<td>Blueprint Life Science Group<\/td>\n<\/tr>\n<tr>\n<td>+61 1300 550 310 | +61 7 3152 3200<\/td>\n<td>+1 917 330 4269<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:10%;width:10%;min-width:10%\">Website<\/td>\n<td style=\"max-width:90%;width:90%;min-width:90%\">www.anteristech.com<\/td>\n<\/tr>\n<tr>\n<td>X<\/td>\n<td>@AnterisTech<\/td>\n<\/tr>\n<tr>\n<td>LinkedIn<\/td>\n<td>https:\/\/www.linkedin.com\/company\/anteristech<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        \n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODIyMyM3OTY2NzcwIzIyNjIyMTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OGEwYjIwZTAtYTdmNi00MDFjLWFkZDAtNDkxMzJiOTdjZjM3LTEyNzM3NjMtMjAyNi0xMS0xNi1lbg==\/tiny\/Anteris-Technologies-Pty-Ltd.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MINNEAPOLIS and BRISBANE, Australia, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; Anteris Technologies Global Corp. (\u201cAnteris\u201d or the \u201cCompany\u201d) (Nasdaq: AVR; ASX: AVR) today announced that Rishi Puri, MD, PhD, Cleveland Clinic, will present one-year clinical and hemodynamic outcomes for the DurAVR\u00ae Transcatheter Heart Valve (THV) in a late-breaking session at PCR London Valves, held November 22\u201324, 2026, in London, United Kingdom. The presentation will report one-year clinical and hemodynamic outcomes from a pooled cohort of 100 patients with severe aortic stenosis who received the DurAVR THV. The DurAVR THV is a biomimetic, balloon-expandable valve and a new class of transcatheter aortic valve replacement (TAVR). Session details are as follows: Session: TAVI Hotline \u2013 Part 1Track: Hotline \/ Late-Breaking TrialsDate and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021148","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MINNEAPOLIS and BRISBANE, Australia, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; Anteris Technologies Global Corp. (\u201cAnteris\u201d or the \u201cCompany\u201d) (Nasdaq: AVR; ASX: AVR) today announced that Rishi Puri, MD, PhD, Cleveland Clinic, will present one-year clinical and hemodynamic outcomes for the DurAVR\u00ae Transcatheter Heart Valve (THV) in a late-breaking session at PCR London Valves, held November 22\u201324, 2026, in London, United Kingdom. The presentation will report one-year clinical and hemodynamic outcomes from a pooled cohort of 100 patients with severe aortic stenosis who received the DurAVR THV. The DurAVR THV is a biomimetic, balloon-expandable valve and a new class of transcatheter aortic valve replacement (TAVR). Session details are as follows: Session: TAVI Hotline \u2013 Part 1Track: Hotline \/ Late-Breaking TrialsDate and &hellip; Continue reading &quot;Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T11:04:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODIyMyM3OTY2NzcwIzIyNjIyMTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients\",\"datePublished\":\"2026-11-16T11:04:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\\\/\"},\"wordCount\":529,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODIyMyM3OTY2NzcwIzIyNjIyMTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\\\/\",\"name\":\"Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODIyMyM3OTY2NzcwIzIyNjIyMTM=\",\"datePublished\":\"2026-11-16T11:04:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODIyMyM3OTY2NzcwIzIyNjIyMTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODIyMyM3OTY2NzcwIzIyNjIyMTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/","og_locale":"en_US","og_type":"article","og_title":"Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients - Market Newsdesk","og_description":"MINNEAPOLIS and BRISBANE, Australia, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; Anteris Technologies Global Corp. (\u201cAnteris\u201d or the \u201cCompany\u201d) (Nasdaq: AVR; ASX: AVR) today announced that Rishi Puri, MD, PhD, Cleveland Clinic, will present one-year clinical and hemodynamic outcomes for the DurAVR\u00ae Transcatheter Heart Valve (THV) in a late-breaking session at PCR London Valves, held November 22\u201324, 2026, in London, United Kingdom. The presentation will report one-year clinical and hemodynamic outcomes from a pooled cohort of 100 patients with severe aortic stenosis who received the DurAVR THV. The DurAVR THV is a biomimetic, balloon-expandable valve and a new class of transcatheter aortic valve replacement (TAVR). Session details are as follows: Session: TAVI Hotline \u2013 Part 1Track: Hotline \/ Late-Breaking TrialsDate and &hellip; Continue reading \"Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-16T11:04:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODIyMyM3OTY2NzcwIzIyNjIyMTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients","datePublished":"2026-11-16T11:04:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/"},"wordCount":529,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODIyMyM3OTY2NzcwIzIyNjIyMTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/","name":"Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODIyMyM3OTY2NzcwIzIyNjIyMTM=","datePublished":"2026-11-16T11:04:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODIyMyM3OTY2NzcwIzIyNjIyMTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODIyMyM3OTY2NzcwIzIyNjIyMTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anteris-announces-late-breaking-pcr-london-valves-data-release-one-year-duravr-thv-outcomes-in-100-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021148"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021148\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}